Literature DB >> 18056482

Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation.

Jason W Chien1, Michael J Boeckh, John A Hansen, Joan G Clark.   

Abstract

Lipopolysaccharide binding protein (LBP) function is dependent on circulating LBP levels. Disturbance of LBP transcription regulation may influence the risk for clinical events. In a nested case-control study using a single nucleotide polymorphism haplotype tagging (tagSNP) approach, we assessed whether genetic variation in the LBP gene influences the risk for Gram-negative (GN) bacteremia after allogeneic hematopoietic cell transplantation (HCT), then validated the association in a prospective cohort by correlating genetic variation with basal serum LBP levels and mortality. Presence of the tagSNP 6878 C allele among patients was associated with a 2-fold higher risk for GN bacteremia (odds ratio = 2.15; 95% confidence interval [CI], 1.31-3.52, P = .002). TagSNP 6878 was in strong linkage disequilibrium with 3 SNPs in the LBP promoter, one of which was SNP 1683 (r(2) = 0.8), located in a CAAT box that regulates LBP promoter efficiency. SNP 1683 was associated with higher median basal serum LBP levels (TT 8.07 microg/mL; TC 10.40 microg/mL; CC 17.39 microg/mL; P = .002), and a 5-fold increase in GN bacteremia related mortality after HCT (hazard ratio = 4.83; 95% CI, 1.38-16.75, P = .013). These data suggest that transcriptional regulation of the LBP gene contributes to the risk for developing GN bacteremia and death after HCT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056482      PMCID: PMC2234070          DOI: 10.1182/blood-2007-09-101709

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms.

Authors:  Lutz Hamann; Christian Alexander; Cordula Stamme; Ulrich Zähringer; Ralf R Schumann
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.

Authors:  N Lamping; R Dettmer; N W Schröder; D Pfeil; W Hallatschek; R Burger; R R Schumann
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

3.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

4.  Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.

Authors:  D Przepiorka; T L Smith; J Folloder; I Khouri; N T Ueno; R Mehra; M Körbling; Y O Huh; S Giralt; J Gajewski; M Donato; K Cleary; D Claxton; I Braunschweig; K van Besien; B S Andersson; P Anderlini; R Champlin
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

5.  The transcriptional activation pattern of lipopolysaccharide binding protein (LBP) involving transcription factors AP-1 and C/EBP beta.

Authors:  C J Kirschning; A Unbehaun; G Fiedler; W Hallatschek; N Lamping; D Pfeil; R R Schumann
Journal:  Immunobiology       Date:  1997-12       Impact factor: 3.144

6.  The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins.

Authors:  R R Schumann; C J Kirschning; A Unbehaun; H P Aberle; H P Knope; N Lamping; R J Ulevitch; F Herrmann
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

7.  Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.

Authors:  S M Opal; P J Scannon; J L Vincent; M White; S F Carroll; J E Palardy; N A Parejo; J P Pribble; J H Lemke
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

8.  Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins.

Authors:  M M Wurfel; S D Wright
Journal:  Prog Clin Biol Res       Date:  1995

9.  Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14.

Authors:  J A Gegner; R J Ulevitch; P S Tobias
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

10.  Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact.

Authors:  M M Wurfel; B G Monks; R R Ingalls; R L Dedrick; R Delude; D Zhou; N Lamping; R R Schumann; R Thieringer; M J Fenton; S D Wright; D Golenbock
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

View more
  18 in total

1.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

2.  Plasma lipopolysaccharide-binding protein and colorectal cancer risk: a nested case-control study in the Multiethnic Cohort.

Authors:  Jessica S Citronberg; Lynne R Wilkens; Loic Le Marchand; Unhee Lim; Kristine R Monroe; Meredith A J Hullar; Emily White; Polly A Newcomb; Johanna W Lampe
Journal:  Cancer Causes Control       Date:  2017-11-30       Impact factor: 2.506

3.  Mutations in lipopolysaccharide-binding protein (LBP) gene change the susceptibility to clinical mastitis in Chinese Holstein.

Authors:  Jienan Cheng; Jun Li; Wenxin Zhang; Yafei Cai; Genlin Wang
Journal:  Mol Biol Rep       Date:  2012-06-26       Impact factor: 2.316

Review 4.  NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges.

Authors:  Smita Bhatia; Stella M Davies; K Scott Baker; Michael A Pulsipher; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-18       Impact factor: 5.742

Review 5.  Improving hematopoietic cell transplant outcomes in a new era of genomic research.

Authors:  Jason W Chien; Lue Ping Zhao; Barry Storer; Paul J Martin; Michael Boeckh; Edus H Warren; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 6.  Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today?

Authors:  Lucy E Horton; Nina M Haste; Randy A Taplitz
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

Review 7.  Risk stratification and immunogenetic risk for infections following stem cell transplantation.

Authors:  Agnieszka Wójtowicz; Pierre-Yves Bochud
Journal:  Virulence       Date:  2016-09-09       Impact factor: 5.882

8.  Synergy between acid and endotoxin in an experimental model of aspiration-related lung injury progression.

Authors:  Konstantin Tetenev; Mary E Cloutier; Jessica A von Reyn; Jennifer L Ather; James Candon; Gilman B Allen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-25       Impact factor: 5.464

9.  Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes.

Authors:  Bart L Scott; J Y Park; H Joachim Deeg; Kieren A Marr; Michael Boeckh; Thomas R Chauncey; Frederick R Appelbaum; Rainer Storb; Barry E Storer
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

10.  Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis.

Authors:  Jesús Villar; Lina Pérez-Méndez; Elena Espinosa; Carlos Flores; Jesús Blanco; Arturo Muriel; Santiago Basaldúa; Mercedes Muros; Lluis Blanch; Antonio Artigas; Robert M Kacmarek
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.